Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MV-CHIK Vaccine in Healthy Volunteers
NCT03635086Phase 2Completed
- Sponsor
- Themis Bioscience
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Viral Vectors, Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MV-CHIK in chikungunya virus infection (5 arms), sponsored by Themis Bioscience. Primary endpoint: Geometric Mean Titer of Anti-Chikungunya Antibodies as Measured by 50% Plaque Reduction Neutralization Test. Started Aug 2018; status: completed.
02
Drugs
MV-CHIK
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT03635086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635086.